The T2Candida® Panel is the first and only FDA-cleared and CE-marked direct-from-blood fungal pathogen detection assay, providing same-day results directly from a whole blood specimen for the most clinically relevant fungi.
Candida infections have an overall mortality rate of 40%, but if patients receive targeted treatment within 12 hours, the mortality rate can be reduced to 11%.2,3 T2Candida provides a clear and compelling solution, with results in just hours without waiting for slow-growing fungal infections, which are often mistaken as bacterial infections, to reach positivity.
The T2Candida Panel pivotal clinical trial demonstrated results in 3 to 5 hours.4 All other FDA-cleared Candida diagnostic methods require a positive blood culture. Blood culture misses up to half of the infections and often will take 2 to 8 days to become positive.5 Only then can identification be performed. In most cases, a negative result is not confirmed for 5 days after collection and processing of the blood culture.
Faster time to appropriate therapy has been consistently demonstrated to reduce the overall length of stay in the hospital and ICU and results in a savings of $30,000 per patient.6 See how Henry Ford in Michigan and Lee Health in Florida have demonstrated faster-targeted therapy for patients in clinical care for more than 24 hours.7,8
Watch T2Candida at work.
Contact us to request a demo of the T2Candida Panel!
……………………………………….
1. Clancy CJ and Nguyen MH. Diagnostic Microbiology and Infectious Disease, 2018
2. Morrell M, et al. Antimicrobial Agents and Chemotherapy, 2005
3. Garey KW, et al. Clinical Infectious Diseases, 2006
4. Mylonakis E, et al. Clinical Infectious Diseases, 2015
5. Clancy CJ and Nguyen MH. Clinical Infectious Diseases, 2013
6. Arnold HM, et al. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
7. Wilson NM, et al. The Journal of Antimicrobial Stewardship, 2017
T2 Biosystems
101 Hartwell Avenue
Lexington, MA 02421
Phone: 781-457-1200
Fax: 781-357-3080
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, T2Resistance® and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Lyme™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
© 2024 T2 Biosystems, Inc.
Please tell us where you are visiting from: United States | Outside the United States
